Anti-MOG antibody disease (MOGAD): treatment
Evidence-based neurology checklist on anti-mog antibody disease (mogad): treatment: Acute treatment Methylprednisolone Plasma exchange Intravenous immunoglobulins (IVIg) Long-term maintenance treatment Ineffective treatments Treatment withdrawal
Acute treatment
- Methylprednisolone
- Plasma exchange
- Intravenous immunoglobulins (IVIg)
Long-term maintenance treatment
Ineffective treatments
Treatment withdrawal
References
- Jarius S, Ruprecht K, Kleiter I, et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13:280.
- Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018; 75:478-487.
- Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020; 95:e111-e120.
- Vilardo M, Mahler JV, Leles Vieira de Souza B, et al. Effectiveness and safety of plasmapheresis in MOGAD attacks: a systematic review and meta-analysis. Neurology 2026; 107:e218300.
- Tsantes E, Curti E, Siena E, Granella F. Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. Mult Scler Relat Disord 2019; 32:27-29.
- And 9 more. Subscribe to see the full list
